gilead
sciences
breaking
news
nightly
remdesivir
approved
for
emergency
use
by
fda
ews
2
mfda
u.s.
department
of
health
and
human
services
food
drug
administration
ws
*********
eir
clinical
trial
se
only
(gs-5734)
inge
cantents:
each
vial
contare
lyophilized
powder
intravenou
bare
below
30%
drections:see
cling
(stuo)
dosage
acinmeration
kamp
out
rench
chiltren
caution:new
drug-limite
nbc
********
nbcnews
daniel
o'day
ceo
ggilead
jews
from
5,000
to
100,000
millions
the
end
2020
ight
nbcne
nih
national
institutes
shows
accelerates
in
recovery
advanced
covid-19
pril
29,2
contents:each
contains
ophilized
patients
who
received
placebo,
according
a
preliminary
data
analysis
randomized,
controlled
involving
1063
atients,
which
began
on
february
21.
(known
as
adaptive
treatment
trial,
or
actt),
sponsored
nstitute
allergy
infectious
diseases
(niaid),
part
health,
is
first
launched
th
bore
30
c
swing
tral
met
aprli
27
review
shared
their
interim
took
nih)
inflest
april
29,2020
contain
lophilized
ant
safety
monitoring
board
shater
they
noted
that
rem
delly
was
better
than
placebo
ned
improved
31%
faster
those
taking
institutos
remdesivir(gs-5734)
injaction
hospitalized
with
lung
involvement
recovered
similar
jnited
states
evaluate
an
experimental
covid-19.
independent
(dsmb)
overseeing
iew
data,
used
infuenza
trals.
this
study
define
&
injuction
contents:
sore
30'c
mon
order
not
same
official
approval
store
m
8teven
niasen,
m.d.
vvs
eveland
clite
improve
chances
survival?
breakingnews
does
do
any
harm?
nghtly
pabit
t'll
you
blue
ribb
i
your
thin
bluo
家
watch
more
山国
wuvi
ghtly
lester
hoit
subscribe
nifws
n
251
o
福语语画量：
